Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6414) 6414
Newsletter (73) 73
Book Chapter (41) 41
Newspaper Article (32) 32
Magazine Article (27) 27
Dissertation (3) 3
Conference Proceeding (2) 2
Government Document (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5458) 5458
science & technology (4480) 4480
life sciences & biomedicine (4298) 4298
male (3439) 3439
female (3342) 3342
hepatitis c, chronic - drug therapy (3245) 3245
ribavirin - administration & dosage (3184) 3184
ribavirin (3003) 3003
ribavirin - therapeutic use (2974) 2974
drug therapy, combination (2949) 2949
middle aged (2868) 2868
antiviral agents - therapeutic use (2843) 2843
antiviral agents - administration & dosage (2717) 2717
adult (2623) 2623
hepatitis c (2332) 2332
treatment outcome (2156) 2156
interferon-alpha - administration & dosage (2076) 2076
interferon-alpha - therapeutic use (1882) 1882
gastroenterology & hepatology (1756) 1756
infectious diseases (1731) 1731
recombinant proteins (1679) 1679
hepacivirus - genetics (1621) 1621
interferon (1621) 1621
hepatitis c virus (1588) 1588
genotype (1467) 1467
biological and medical sciences (1456) 1456
medical sciences (1436) 1436
aged (1344) 1344
antiviral agents - adverse effects (1328) 1328
ribavirin - adverse effects (1242) 1242
antiviral agents (1240) 1240
polyethylene glycols - administration & dosage (1211) 1211
hepatitis c, chronic - virology (1137) 1137
polyethylene glycols - therapeutic use (1134) 1134
hepatitis (1082) 1082
hepatitis c - drug therapy (1081) 1081
viral diseases (945) 945
health aspects (940) 940
interferon-alpha - adverse effects (938) 938
hepacivirus - drug effects (914) 914
drug therapy (912) 912
human viral diseases (872) 872
pharmacology. drug treatments (858) 858
virology (833) 833
care and treatment (806) 806
viral load (793) 793
biological response modifiers (759) 759
viral hepatitis (747) 747
pharmacology & pharmacy (745) 745
hepatitis c, chronic - complications (661) 661
rna, viral - blood (649) 649
antibiotics. antiinfectious agents. antiparasitic agents (640) 640
drug administration schedule (601) 601
recombinant proteins - therapeutic use (598) 598
abridged index medicus (592) 592
infections (580) 580
recombinant proteins - administration & dosage (570) 570
viruses (569) 569
virus diseases (542) 542
dosage and administration (534) 534
retrospective studies (523) 523
analysis (522) 522
time factors (520) 520
polyethylene glycols - adverse effects (514) 514
genetic aspects (509) 509
microbiology (508) 508
immunology (489) 489
chronic hepatitis c (487) 487
animals (480) 480
risk factors (477) 477
research (472) 472
adolescent (456) 456
prospective studies (453) 453
young adult (452) 452
liver (449) 449
genotypes (444) 444
patients (436) 436
gastroenterology and hepatology (428) 428
antiviral agents - pharmacology (426) 426
general & internal medicine (425) 425
genotype & phenotype (425) 425
hepacivirus - isolation & purification (423) 423
recurrence (415) 415
ribavirin - pharmacology (400) 400
medicine, general & internal (398) 398
dose-response relationship, drug (395) 395
hiv infections - complications (374) 374
interferons - therapeutic use (372) 372
hepatology (356) 356
polyethylene glycols (352) 352
follow-up studies (343) 343
liver cirrhosis (340) 340
hcv (339) 339
interferons - administration & dosage (336) 336
hepatitis c, chronic - genetics (332) 332
transplantation (329) 329
cirrhosis (325) 325
hepatitis c - complications (322) 322
hepatitis c - virology (308) 308
clinical trials (307) 307
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6168) 6168
Japanese (100) 100
Spanish (84) 84
German (81) 81
French (80) 80
Russian (58) 58
Chinese (47) 47
Portuguese (45) 45
Polish (40) 40
Korean (20) 20
Hungarian (19) 19
Croatian (14) 14
Italian (14) 14
Czech (10) 10
Serbian (9) 9
Dutch (4) 4
Turkish (4) 4
Norwegian (3) 3
Slovak (3) 3
Swedish (3) 3
Danish (2) 2
Hebrew (2) 2
Bosnian (1) 1
Finnish (1) 1
Romanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Management of direct-acting antiviral agent failures
by Buti, Maria and Riveiro-Barciela, Mar and Esteban, Rafael
Journal of hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real world cohort
by Calleja, Jose Luis and Crespo, Javier and Rincón, Diego and Ruiz-Antorán, Belén and Fernandez, Inmaculada and Perelló, Christie and Gea, Francisco and Lens, Sabela and García-Samaniego, Javier and Sacristán, Begoña and García-Eliz, María and Llerena, Susana and Pascasio, Juan Manuel and Turnes, Juan and Torras, Xavier and Morillas, Rosa Maria and Llaneras, Jordi and Serra, Miguel A and Diago, Moises and Fernández Rodriguez, Conrado and Ampuero, Javier and Jorquera, Francisco and Simon, Miguel A and Arenas, Juan and Navascues, Carmen Alvarez and Bañares, Rafael and Muñoz, Raquel and Albillos, Agustin and Mariño, Zoe and The Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group and Spanish Grp Study Use and Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group
Journal of hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1138 - 1148
Gastroenterology and Hepatology | Antiviral agents | Ombitasvir | Ritonavir | Ledipasvir | Real-world | Genotype 1 | Paritaprevir | Sustained virologic response | Hepatitis C, Chronic | Sofosbuvir | Dasabuvir | Randomized controlled trials | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Neoplasm Recurrence, Local - etiology | Liver Neoplasms - etiology | Young Adult | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Drug Therapy, Combination | Glomerular Filtration Rate | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Spain | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Genetic aspects | Safety and security measures | Hepatitis C virus | Clinical trials | Chronic infection | Data processing | Hepatocellular carcinoma | Multivariate analysis | Patients | Clinical outcomes | Ribavirin | Genotype & phenotype | Cohort analysis | Fibrosis | Safety | Drug therapy | Hepatitis C | Antiviral drugs | Genotypes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis c virus genotype 1-coinfected patients treated in routine practice
by Bhattacharya, Debika and Belperio, Pamela S and Shahoumian, Troy A and Loomis, Timothy P and Goetz, Matthew B and Mole, Larry A and Backus, Lisa I
Clinical infectious diseases, ISSN 1058-4838, 06/2017, Volume 64, Issue 12, pp. 1711 - 1720
real-world | HCV | HIV | DAA | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Uridine Monophosphate - administration & dosage | Anilides - therapeutic use | Hepatitis C - drug therapy | Coinfection - drug therapy | Veterans | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Practice Patterns, Physicians | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Female | Fluorenes - administration & dosage | Hepatitis C - complications | Registries | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Administration, Oral | Antiviral Agents - therapeutic use | HIV Infections - virology | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Antiviral Agents - administration & dosage | Coinfection - virology | Macrocyclic Compounds - therapeutic use | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | Hepatitis C - virology | HIV Infections - drug therapy | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Cohort Studies | Antiviral agents | Care and treatment | Dosage and administration | Hepatitis C | HIV infection | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
by Jacobson, Ira M, Prof and Dore, Gregory J, Prof and Foster, Graham R, Prof and Fried, Michael W, Prof and Radu, Monica, MD and Rafalsky, Vladimir V, Prof and Moroz, Larysa, Prof and Craxi, Antonio, Prof and Peeters, Monika, MSc and Lenz, Oliver, PhD and Ouwerkerk-Mahadevan, Sivi, PhD and De La Rosa, Guy, MD and Kalmeijer, Ronald, MD and Scott, Jane, PhD and Sinha, Rekha, PhD and Beumont-Mauviel, Maria, PhD
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 403 - 413
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Simeprevir | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Ribavirin - administration & dosage | Sulfonamides - adverse effects | Adult | Female | Drug Therapy, Combination | Sulfonamides - administration & dosage | Patient outcomes | Interferon alpha | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Methods | Analysis | Clinical trials | Genetic aspects | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Hepatitis | Genotype & phenotype | Infections | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
by Manns, Michael, Prof and Marcellin, Patrick, Prof and Poordad, Fred, Prof and de Araujo, Evaldo Stanislau Affonso, PhD and Buti, Maria, Prof and Horsmans, Yves, Prof and Janczewska, Ewa, MD and Villamil, Federico, Prof and Scott, Jane, PhD and Peeters, Monika, MSc and Lenz, Oliver, PhD and Ouwerkerk-Mahadevan, Sivi, PhD and De La Rosa, Guy, MD and Kalmeijer, Ronald, MD and Sinha, Rekha, PhD and Beumont-Mauviel, Maria, PhD
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 414 - 426
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Simeprevir | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Ribavirin - administration & dosage | Adolescent | Adult | Female | Aged | Drug Therapy, Combination | Sulfonamides - administration & dosage | Patient outcomes | Interferon alpha | Drug therapy, Combination | Hepatitis C | Drug therapy | Methods | Ribavirin | Analysis | Clinical trials | Genetic aspects | Interferon | Product development | Biological response modifiers | Hepatitis C virus | Health aspects | Hepatitis | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Ombitasvir, Paritaprevir Co-dosed with Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected with HIV-1 a Randomized Trial
by Sulkowski, Mark S and Eron, Oseph J and Wyles, David and Trinh, Roger and Lalezari, Jay and Wang, Chia and Slim, Jihad and Bhatti, Laveeza and Gathe, Joseph and Ruane, Peter J and Elion, Richard and Bredeek, Fritz and Brennan, Robert and Blick, Gary and Khatri, Amit and Gibbons, Krystal and Hu, Yiran B and Fredrick, Linda and Schnell, Gretja and Pilot-Matias, Tami and Tripathi, Rakesh and Da Silva-Tillmann, Barbara and McGovern, Barbara and Campbell, Andrew L and Podsadecki, Thomas
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1223 - 1231
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | HIV-1 | Coinfection | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Ritonavir - adverse effects | Uracil - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Hepatitis C - complications | Drug Therapy, Combination | Ritonavir - administration & dosage | Treatment Outcome | Macrocyclic Compounds - adverse effects | Antiviral Agents - administration & dosage | Pilot Projects | Uracil - adverse effects | Anilides - administration & dosage | Ribavirin - adverse effects | HIV Infections - complications | Sulfonamides - adverse effects | Carbamates - adverse effects | HIV Infections - drug therapy | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Drugs | Clinical trials | Hepatitis | Human immunodeficiency virus--HIV | Medical treatment
Journal Article
Details down arrow
7. Full Text Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
by Pockros, Paul J and Reddy, K. Rajender and Mantry, Parvez S and Cohen, Eric and Bennett, Michael and Sulkowski, Mark S and Bernstein, David E and Cohen, Daniel E and Shulman, Nancy S and Wang, Deli and Khatri, Amit and Abunimeh, Manal and Podsadecki, Thomas and Lawitz, Eric
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2016, Volume 150, Issue 7, pp. 1590 - 1598
Gastroenterology and Hepatology | NS3/4A Protease Inhibitor | Renal Disease | RUBY-I | NS5A Inhibitor | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Dose-Response Relationship, Drug | Uracil - administration & dosage | Ribavirin - administration & dosage | Female | Hepatitis C - complications | Drug Therapy, Combination | Ritonavir - administration & dosage | Kidney Failure, Chronic - drug therapy | Genotype | Antiviral Agents - administration & dosage | Anilides - administration & dosage | Kidney Failure, Chronic - virology | Hepatitis C - virology | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Antiviral agents | Care and treatment | Chronic kidney failure | Analysis | Communicable diseases | Liver | Genetic aspects | Hepatitis C virus | Health aspects | Restaurants | Protease inhibitors | Proteases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis
by Kwo, Paul Y and Poordad, Fred and Asatryan, Armen and Wang, Stanley and Wyles, David L and Hassanein, Tarek and Felizarta, Franco and Sulkowski, Mark S and Gane, Edward and Maliakkal, Benedict and Scott Overcash, J and Gordon, Stuart C and Muir, Andrew J and Aguilar, Humberto and Agarwal, Kosh and Dore, Gregory J and Lin, Chih-Wei and Liu, Ran and Lovell, Sandra S and Ng, Teresa I and Kort, Jens and Mensa, Federico J
Journal of hepatology, ISSN 0168-8278, 2017, Volume 67, Issue 2, pp. 263 - 271
Gastroenterology and Hepatology | SURVEYOR | ABT-530 | Pangenotypic | D-alanine transaminase | Hepatitis C, chronic | Interferons | Direct-acting antiviral | Genotype | ABT-493 | Sustained virologic response | Liver cirrhosis | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Quinoxalines - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Adult | Female | Benzimidazoles - adverse effects | Drug Therapy, Combination | Hepacivirus - drug effects | Drug Administration Schedule | Drug Resistance, Multiple, Viral - genetics | Quinoxalines - administration & dosage | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polymorphism, Genetic | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Aged | Sustained Virologic Response | Sulfonamides - administration & dosage | Alanine | Clinical trials | Chronic infection | Viruses | Proteinase inhibitors | Patients | Ribavirin | Hepatitis | Genotype & phenotype | Cirrhosis | Alanine transaminase | Interferon | Hepatitis C | Antiviral drugs | Genotypes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
by Mizokami, Masashi, Prof and Yokosuka, Osamu, Prof and Takehara, Tetsuo, Prof and Sakamoto, Naoya, Prof and Korenaga, Masaaki, MD and Mochizuki, Hitoshi, MD and Nakane, Kunio, MD and Enomoto, Hirayuki, MD and Ikeda, Fusao, MD and Yanase, Mikio, MD and Toyoda, Hidenori, MD and Genda, Takuya, MD and Umemura, Takeji, MD and Yatsuhashi, Hiroshi, Prof and Ide, Tatsuya, MD and Toda, Nobuo, MD and Nirei, Kazushige and Ueno, Yoshiyuki, Prof and Nishigaki, Yoichi, MD and Betular, Juan, BS and Gao, Bing, PhD and Ishizaki, Akinobu, BA and Omote, Masa, PhD and Mo, Hongmei, MD and Garrison, Kim, PhD and Pang, Phillip S, MD and Knox, Steven J, BS and Symonds, William T, PharmD and McHutchison, John G, MD and Izumi, Namiki, Prof and Omata, Masao, Prof
The Lancet infectious diseases, ISSN 1473-3099, 2015, Volume 15, Issue 6, pp. 645 - 653
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Benzimidazoles - administration & dosage | Time Factors | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Hepacivirus - isolation & purification | Administration, Oral | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Asian Continental Ancestry Group | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Liver | Dosage and administration | Product development | Drug therapy, Combination | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Liver cancer | Heart attacks | Liver diseases | Human immunodeficiency virus--HIV | Hepatology | Response rates | Interferon | Infections | Drug dosages | Patients | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights